PEGylated recombinant human arginase as a drug for
breast cancer
SL Leung, MK Ho, YM Lam, HY Chow, YH So, YC
Leung
Department of Applied Biology and Chemical
Technology, and Lo Ka Chung Centre for Natural Anti-Cancer Drug
Development, The Hong Kong Polytechnic University
1. rhArg-PEG is highly potent and kills all breast
cancer cell lines (including ‘triple-negative’ and highly aggressive
metastatic cells) in vitro and in vivo in a receptor-independent manner.
2. rhArg-PEG induces multiple cancer cell death pathways that are cell-line dependent.
3. rhArg-PEG inhibits mTOR, activates AMPK, and induces a novel type of biphasic autophagic response in cancer cells, leading to autophagic cell death.
4. rhArg-PEG kills cancer cells lacking ornithine transcarbamylase and/or argininosuccinate synthetase and inhibits more tumours than arginine deiminase-PEG does. It is a promising personalised medicine.
2. rhArg-PEG induces multiple cancer cell death pathways that are cell-line dependent.
3. rhArg-PEG inhibits mTOR, activates AMPK, and induces a novel type of biphasic autophagic response in cancer cells, leading to autophagic cell death.
4. rhArg-PEG kills cancer cells lacking ornithine transcarbamylase and/or argininosuccinate synthetase and inhibits more tumours than arginine deiminase-PEG does. It is a promising personalised medicine.